Targovax to present at forthcoming conferences
(Thomson Reuters ONE) -
Oslo 14 September 2016: Targovax (OSE: TRVX, or "the Company"), a clinical stage
company developing targeted immunotherapy treatments for cancer patients,
announces that members of its senior management will present at the following
conferences:
Nordic Life Science Days
Date: 14 September 2016
Participants: Gunnar Gårdemyr (CEO) and Peter Skorpil (VP BD)
Presentation time: 17:15 CET
Venue: Waterfront Congress Center, Stockholm, Sweden
Sachs Associates: 16(th) Annual Biotech in Europe forum
Date: 28 September 2016
Participant: Gunnar Gårdemyr (CEO)
Presentation time: 09:45 CET
Venue: Congress Center, Basel, Switzerland
Cutting Edge / Oslo Innovation Week
Date: 18 October 2016
Participant: Peter Skorpil (VP BD)
Presentation time: 11:40 CET
Venue: Oslo Science Park, Oslo, Norway
Teknologirevolusjon innen kreftterapi
Date: 26 October 2016
Participant: Magnus Jaderberg (CMO)
Presentation time: 11:20 CET
Venue: Oslo Cancer Cluster, Oslo, Norway
Presentations will be available to download at www.targovax.com following these
events.
For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr(at)targovax.com
Øystein Soug, CFO
Phone: +47 90 6565 25
Email: oystein.soug(at)targovax.com
Media and IR enquires:
Jan Petter Stiff - Crux Advisors (Norway)
Phone: +47 995 13 891
Email: jps(at)crux.no
Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax(at)FTIconsulting.com
About Targovax
Arming the patient's immune system to fight cancer
Targovax (OSE: TRVX) is a clinical stage immuno-oncology company developing
targeted immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aims to become a world leader in its
area. The company is currently developing two complementary and highly targeted
approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered
oncolytic viruses armed with potent immune-stimulating transgenes targeting
solid tumors. This treatment is designed to reactivate the immune system's
capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the
difficult to treat RAS mutations found in more than 85% of pancreatic cancers,
50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.
These product candidates will be developed in combination with multiple
treatments, including checkpoint inhibitors in several cancer indications.
Targovax also has a number of other cancer immune therapy candidates in the
early stages of development.
In July 2016 the Company listed its shares on Oslo Axess, securing funding for
further development of the Company's ongoing and planned trials
This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 14.09.2016 - 08:00 Uhr
Sprache: Deutsch
News-ID 494639
Anzahl Zeichen: 4018
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 199 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax to present at forthcoming conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
